FDA clears Moderna’s mRNA flu vaccine mFLUSIVA for adults 50 and older
AI Market Summary
FDA approval of Moderna's mRNA flu vaccine (mFLUSIVA) marks the first mRNA influenza shot cleared in the U.S., reinforcing the commercial viability of Moderna's platform despite prior political and regulatory friction. The revised filing pathway and commitments for additional elderly studies reduce near-term regulatory overhang, though the launch timeline (2026–27 season) limits immediate revenue impact. Overall, the decision supports sentiment toward Moderna's pipeline credibility.
Impact level
● Medium
Affected assets
NCSKMRNA2USD/USDT-0.02%
AI Insight · NCSKMRNA2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
The U.S. Food and Drug Administration has approved Moderna’s mRNA-based seasonal flu vaccine, mFLUSIVA, for adults ages 50 and older, making it the first mRNA influenza shot cleared by the agency. The decision follows earlier pushback over the company’s application and broader criticism of mRNA technology, after Moderna revised its filing. Moderna said it expects mFLUSIVA to be available for the 2026-27 flu season.
